Stay updated on Nivolumab vs Dacarbazine in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab vs Dacarbazine in Melanoma Clinical Trial page.

Latest updates to the Nivolumab vs Dacarbazine in Melanoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedAdded Naples, Italy, 80131 as a study location and removed Napoli, Italy, 80131.SummaryDifference0.0%

- Check15 days agoChange DetectedAdded Melanoma and related topics (MedlinePlus Genetics) and updated site revision from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check22 days agoChange DetectedSite revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check29 days agoChange DetectedRemoved the Melanoma condition tag and the MedlinePlus Genetics related topic link from the study page.SummaryDifference0.1%

- Check36 days agoChange DetectedAdded related topics: Melanoma and MedlinePlus Genetics.SummaryDifference0.1%

- Check44 days agoChange DetectedThe changes remove the related topics Melanoma and MedlinePlus Genetics from the page's topics section, which does not affect core trial data or the primary purpose of the page; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Nivolumab vs Dacarbazine in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab vs Dacarbazine in Melanoma Clinical Trial page.